Seeking Alpha

Kairos Pharma to Participate in The Microcap Conference in January 2025

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, ...
Yahoo Finance

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

LOS ANGELES, January 28, 2025--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the ...
Seeking Alpha

Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference

Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, ...
Yahoo Finance

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

LOS ANGELES, September 03, 2025--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces ...
Morningstar

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a ...
Morningstar

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...
Investing

Kairos Pharma to present initial phase 1 data for lung cancer drug at conference

Kairos Pharma is currently conducting a Phase 2 clinical trial of ENV105 for castrate-resistant prostate cancer alongside this Phase 1 trial for lung cancer. The clinical-stage biopharmaceutical ...
Finanznachrichten

Kairos Pharma, Ltd: Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data ...